argenx (NASDAQ:ARGX) will discontinue its Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren's disease after an interim analysis found the trial could not meet its primary endpoint.
Argenx SE (NASDAQ:ARGX) shares are in focus after the U.S. Food and Drug Administration accepted a supplemental Biologics License Application for Vyvgart with Priority Review, potentially expanding the drug's reach to a difficult-to-treat subset of patients with generalized myasthenia gravis (gMG).
Argenx (ARGX) announced the discontinuation of its Phase 3 UplighTED studies for efgartigimod SC in Thyroid Eye Disease (TED) after an interim analysis by an Independent Data Monitoring Committee (IDMC) indicated futility.
Immunology pioneer argenx (NASDAQ:ARGX) delivered its first-ever year of operating profitability in 2025, powered by a massive commercial expansion of its flagship FcRn blocker, VYVGART.
Argenx SE (NASDAQ:ARGX) announced a significant leadership transition on Monday, appointing Chief Operating Officer Karen Massey as its new Chief Executive Officer and Executive Director, effective immediately.
Amsterdam, Netherlands- and Boston-based argenx SE (NASDAQ:ARGX), a global immunology company, reported preliminary full-year 2025 global product net sales of $4.15 billion, reflecting strong commercial momentum for its flagship FcRn antagonist VYVGART (efgartigimod) and its subcutaneous formulation VYVGART Hytrulo.
